TY - JOUR
T1 - Pulmonary function tests in extremely low gestational age infants at one year of age
AU - Voynow, Judith A.
AU - Feng, Rui
AU - Ren, Clement L.
AU - Dylag, Andrew M.
AU - Kemp, James S.
AU - McDowell, Karen
AU - Sharp, Jack
AU - Moore, Paul E.
AU - Eichenwald, Eric
AU - Panitch, Howard
AU - Clem, Charles
AU - Johnson, Robin
AU - Davis, Stephanie D.
N1 - Funding Information:
We would like to acknowledge the critical work of the PROP Site and Data Coordinating Center Investigators and research staff, the support of Lynn Taussig, MD, University of Denver, and of Carol J. Blaisdell, MD, Division of Lung Diseases, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA for their guidance. We are most of all indebted to the generosity of our NICU families who consented to this and other research studies. PROP Investigators and Research Staff are listed in the Appendix. Supported by National Institutes of Health, NHLBI and NICHD through U01 HL101794 to University of Pennsylvania, B Schmidt; U01 HL101456 to Vanderbilt University, JL Aschner, and PE Moore; U01 HL101798 to University of California San Francisco, PL Ballard, and RL Keller; U01 HL101813 to University of Rochester and University at Buffalo, GS Pryhuber, R Ryan, and T Mariani; U01 HL101465 to Washington University, A Hamvas and T Ferkol; U01 HL101800 to Cincinnati Children's Hospital Medical Center, AH Jobe, and CA Chougnet; and 5R01HL105702 to Indiana University and Duke University, CM Cotten, SD Davis, and JA Voynow.
Funding Information:
We would like to acknowledge the critical work of the PROP Site and Data Coordinating Center Investigators and research staff, the support of Lynn Taussig, MD, University of Denver, and of Carol J. Blaisdell, MD, Division of Lung Diseases, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA for their guidance. We are most of all indebted to the generosity of our NICU families who consented to this and other research studies. PROP Investigators and Research Staff are listed in the Appendix. Supported by National Institutes of Health, NHLBI and NICHD through U01 HL101794 to University of Pennsylvania, B Schmidt; U01 HL101456 to Vanderbilt University, JL Aschner, and PE Moore; U01 HL101798 to University of California San Francisco, PL Ballard, and RL Keller; U01 HL101813 to University of Rochester and University at Buffalo, GS Pryhuber, R Ryan, and T Mariani; U01 HL101465 to Washington University, A Hamvas and T Ferkol; U01 HL101800 to Cincinnati Children's Hospital Medical Center, AH Jobe, and CA Chougnet; and 5R01HL105702 to Indiana University and Duke University, CM Cotten, SD Davis, and JA Voynow.
Publisher Copyright:
© 2021 Wiley Periodicals LLC
PY - 2022/2
Y1 - 2022/2
N2 - Rationale: Identifying neonatal and post-discharge exposures among extremely low gestational age newborns (ELGANs) that drive increased pulmonary morbidity and abnormal lung function at 1 year of age proves challenging. Objective: The NIH-sponsored Prematurity and Respiratory Outcomes Program (PROP), evaluated infant pulmonary function tests (iPFTs) at 1 year corrected age to determine which demographic and clinical factors are associated with abnormal lung function. Methods: iPFTs were performed on a PROP subcohort of 135 participants following Institutional Review Board (IRB)-approved written consent. Demographic data, Neonatal Intensive Care Unit (NICU) clinical care, and post-NICU exposures were analyzed for association with iPFTs. Main Results: A significant decrease in forced expiratory volume at 0.5 s (FEV0.5) and/or forced expiratory flows at 75% of forced vital capacity (FEF75), were associated with male sex and African American race. Clinical factors including longer duration of ventilatory support, exposure to systemic steroids, and weight less than the 10th percentile at 36 weeks postmenstrual age were also associated with airflow obstruction, whereas supplemental oxygen requirement and bronchopulmonary dysplasia were not. Additionally, the need for respiratory medications, technology, or hospitalizations during the first year, ascertained by a quarterly survey, were the only post-NICU factors associated with decreased FEV0.5 and FEF75. Only 7% of infants had reversible airflow obstruction. Conclusions: Neonatal demographic factors, respiratory support in the NICU, and a history of greater post-NICU medical utilization for respiratory disease had the strongest association with lower lung function at 1 year in ELGANs.
AB - Rationale: Identifying neonatal and post-discharge exposures among extremely low gestational age newborns (ELGANs) that drive increased pulmonary morbidity and abnormal lung function at 1 year of age proves challenging. Objective: The NIH-sponsored Prematurity and Respiratory Outcomes Program (PROP), evaluated infant pulmonary function tests (iPFTs) at 1 year corrected age to determine which demographic and clinical factors are associated with abnormal lung function. Methods: iPFTs were performed on a PROP subcohort of 135 participants following Institutional Review Board (IRB)-approved written consent. Demographic data, Neonatal Intensive Care Unit (NICU) clinical care, and post-NICU exposures were analyzed for association with iPFTs. Main Results: A significant decrease in forced expiratory volume at 0.5 s (FEV0.5) and/or forced expiratory flows at 75% of forced vital capacity (FEF75), were associated with male sex and African American race. Clinical factors including longer duration of ventilatory support, exposure to systemic steroids, and weight less than the 10th percentile at 36 weeks postmenstrual age were also associated with airflow obstruction, whereas supplemental oxygen requirement and bronchopulmonary dysplasia were not. Additionally, the need for respiratory medications, technology, or hospitalizations during the first year, ascertained by a quarterly survey, were the only post-NICU factors associated with decreased FEV0.5 and FEF75. Only 7% of infants had reversible airflow obstruction. Conclusions: Neonatal demographic factors, respiratory support in the NICU, and a history of greater post-NICU medical utilization for respiratory disease had the strongest association with lower lung function at 1 year in ELGANs.
UR - http://www.scopus.com/inward/record.url?scp=85119653261&partnerID=8YFLogxK
U2 - 10.1002/ppul.25757
DO - 10.1002/ppul.25757
M3 - Article
C2 - 34779149
AN - SCOPUS:85119653261
SN - 8755-6863
VL - 57
SP - 435
EP - 447
JO - Pediatric Pulmonology
JF - Pediatric Pulmonology
IS - 2
ER -